東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Non-steroidal anti-inflammatory drug...

Brasky, Theodore Michael.

Linked to FindBook

Google Book

Amazon

博客來

Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 genetic variation, and breast cancer risk.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 genetic variation, and breast cancer risk./
Author:	Brasky, Theodore Michael.
Description:	142 p.
Notes:	Source: Dissertation Abstracts International, Volume: 71-02, Section: B, page: 0902.
Contained By:	Dissertation Abstracts International71-02B.
Subject:	Health Sciences, Epidemiology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3391026
ISBN:	9781109625059

Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 genetic variation, and breast cancer risk.
Brasky, Theodore Michael.

Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 genetic variation, and breast cancer risk. - 142 p.

Source: Dissertation Abstracts International, Volume: 71-02, Section: B, page: 0902.

Thesis (Ph.D.)--State University of New York at Buffalo, 2010.

Chronic inflammation has been consistently associated with cancers of several sites, including the breast. While non-steroidal anti-inflammatory drugs (NSAIDs) have been hypothesized to reduce breast cancer risk, results of studies of this association have been inconsistent. It may be that different tumor types may have different etiology, and that molecular characterizations of breast tumors, such as estrogen and progesterone receptor status (ER and PR), HER2, and p53, need to be taken into account. As NSAIDs are thought to exert their antiinflammatory properties through binding with cyclooxygenase-2 (COX-2), genetic variation in COX-2 may also affect breast cancer risk by affecting inflammatory response and response to NSAID use. Lifetime aspirin and recent use of NSAIDs was examined in a population-based case-control study in western New York State. We identified eight tag SNPs for the COX-2 gene. Cases had incident, primary, histologically confirmed breast cancer (n=1170). Controls (n=2115) were randomly selected from NY Department of Motor Vehicles records (<65yrs) or Medicare rolls (≥65yrs). Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI). Recent ibuprofen use was not associated with decreased risk and there was a suggestion that it was associated with increased risk of ER+/PR+ tumors (OR 1.33, 95% CI: 1.09-1.62); no significant differences were observed for tumors stratified by HER2 or p53. Recent aspirin use was inversely associated with breast cancer risk (OR 0.81, 95% CI: 0.70-0.94); associations were not different by molecular subtype. Lifetime aspirin use per decade of life was inversely associated with risk but not different by ER/PR status. The COX-2 SNP, rs2745559, was associated with an increased risk of breast cancer (OR 1.23, 95% CI: 1.03-1.46). Other variants were associated with small, non-significant decreased risks. We observed significant interaction between recent aspirin use and rs4648261 (p=0.04). No significant interactions were observed with recent ibuprofen or lifetime aspirin use for any of the SNPs. Our findings support existing evidence that aspirin use is inversely associated with risk; however, they do not support the hypothesis that this association differs by tumor subtype. Our finding of an increased risk of ER+/PR+ but not ER-/PR-tumors in association with ibuprofen use may suggest departures in mechanisms of action between aspirin and ibuprofen. Though variation in COX-2 did not substantially affect breast cancer risk, small associations, particularly with rs2745559, were observed.

ISBN: 9781109625059Subjects--Topical Terms:

1019544
Health Sciences, Epidemiology.

Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 genetic variation, and breast cancer risk.
LDR:03650nam 2200289 4500 001 1403133
005 20111111141807.5
008 130515s2010 ||||||||||||||||| ||eng d
020 $a 9781109625059
035 $a (UMI)AAI3391026
035 $a AAI3391026
040 $a UMI $c UMI
100 1 $a Brasky, Theodore Michael. $3 1682380
245 1 0 $a Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 genetic variation, and breast cancer risk.
300 $a 142 p.
500 $a Source: Dissertation Abstracts International, Volume: 71-02, Section: B, page: 0902.
500 $a Adviser: Jo L. Freudenheim.
502 $a Thesis (Ph.D.)--State University of New York at Buffalo, 2010.
520 $a Chronic inflammation has been consistently associated with cancers of several sites, including the breast. While non-steroidal anti-inflammatory drugs (NSAIDs) have been hypothesized to reduce breast cancer risk, results of studies of this association have been inconsistent. It may be that different tumor types may have different etiology, and that molecular characterizations of breast tumors, such as estrogen and progesterone receptor status (ER and PR), HER2, and p53, need to be taken into account. As NSAIDs are thought to exert their antiinflammatory properties through binding with cyclooxygenase-2 (COX-2), genetic variation in COX-2 may also affect breast cancer risk by affecting inflammatory response and response to NSAID use. Lifetime aspirin and recent use of NSAIDs was examined in a population-based case-control study in western New York State. We identified eight tag SNPs for the COX-2 gene. Cases had incident, primary, histologically confirmed breast cancer (n=1170). Controls (n=2115) were randomly selected from NY Department of Motor Vehicles records (<65yrs) or Medicare rolls (≥65yrs). Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI). Recent ibuprofen use was not associated with decreased risk and there was a suggestion that it was associated with increased risk of ER+/PR+ tumors (OR 1.33, 95% CI: 1.09-1.62); no significant differences were observed for tumors stratified by HER2 or p53. Recent aspirin use was inversely associated with breast cancer risk (OR 0.81, 95% CI: 0.70-0.94); associations were not different by molecular subtype. Lifetime aspirin use per decade of life was inversely associated with risk but not different by ER/PR status. The COX-2 SNP, rs2745559, was associated with an increased risk of breast cancer (OR 1.23, 95% CI: 1.03-1.46). Other variants were associated with small, non-significant decreased risks. We observed significant interaction between recent aspirin use and rs4648261 (p=0.04). No significant interactions were observed with recent ibuprofen or lifetime aspirin use for any of the SNPs. Our findings support existing evidence that aspirin use is inversely associated with risk; however, they do not support the hypothesis that this association differs by tumor subtype. Our finding of an increased risk of ER+/PR+ but not ER-/PR-tumors in association with ibuprofen use may suggest departures in mechanisms of action between aspirin and ibuprofen. Though variation in COX-2 did not substantially affect breast cancer risk, small associations, particularly with rs2745559, were observed.
590 $a School code: 0656.
650 4 $a Health Sciences, Epidemiology. $3 1019544
690 $a 0766
710 2 $a State University of New York at Buffalo. $b Social and Preventative Medicine. $3 1682381
773 0 $t Dissertation Abstracts International $g 71-02B.
790 1 0 $a Freudenheim, Jo L., $e advisor
790 1 0 $a Bonner, Matthew R. $e committee member
790 1 0 $a Moysich, Kirsten B. $e committee member
790 $a 0656
791 $a Ph.D.
792 $a 2010
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3391026